Jan R. Dörr

Jan R. Dörr

Auto-generated profile, based on publicly available information

Jan R. Dörr

Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2025 in Cancer Discovery
Verified
Journal Article
Closed access
GMGiulia Montuori
Giulia Montuori
FTFengyu Tu
Fengyu Tu
DQDi Qin
Di Qin
RSRachel Schmargon
Rachel Schmargon
ERElias Rodriguez-Fos
Elias Rodriguez-Fos
JDJan R. Dörr
Jan R. Dörr
Extrachromosomal DNA (ecDNA) amplification enhances intercellular oncogene dosage variability and accelerates tumor evolution by violating foundational principles of genetic inheritance through its asymmetric mitotic segregation. Spotlighting high-risk neuroblastoma, we demonstrate how ecDNA amplification undermines the clinical efficacy of current therapies in cancers with extrachromosomal MYCN amplification. Integrating theoretical models of oncogene copy number–dependent fitness with single-cell ecDNA quantification and phenotype analyses, we reveal that ecDNA copy-number heterogeneity drives phenotypic diversity and determines treatment sensitivity through mechanisms unattainable by chromosomal oncogene amplification. We demonstrate that ecDNA copy number directly influences cell fate decisions in cancer cell lines, patient-derived xenografts, and primary neuroblastomas, illustrating how extrachromosomal oncogene dosage–driven phenotypic diversity offers a strong evolutionary advantage under therapeutic pressure. Furthermore, we identify senescent cells with reduced ecDNA copy numbers as a source of treatment resistance in neuroblastomas and outline a strategy for their targeted elimination to improve the treatment of MYCN-amplified cancers. Significance: ecDNA-driven tumor genome evolution provides a major challenge to curative cancer therapies. We demonstrate that ecDNA copy-number dynamics drives treatment resistance by promoting oncogene dosage–dependent phenotypic heterogeneity in MYCN-amplified cancers. Exploiting phenotype-specific vulnerabilities of ecDNA cells, therefore, presents a powerful strategy to overcome treatment resistance. See related commentary by Korsah, p. 1979

13 January 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
YBYi Bei
Yi Bei
LBLuca Bramé
Luca Bramé
MKMarieluise Kirchner
Marieluise Kirchner
RFRaphaela Fritsche
Raphaela Fritsche
SKSeverine Kunz
Severine Kunz
AHAnton G. Henssen
Anton G. Henssen
DNA amplifications in cancer do not only harbor oncogenes. We sought to determine whether passenger coamplifications could create collateral therapeutic vulnerabilities. Through an analysis of >3,000 cancer genomes followed by the interrogation of CRISPR-Cas9 loss-of-function screens across >700 cancer cell lines, we determined that passenger coamplifications are accompanied by distinct dependency profiles. In a proof-of-principle study, we demonstrate that the coamplification of the bona fide passenger gene DEAD-Box Helicase 1 (DDX1) creates an increased dependency on the mTOR pathway. Interaction proteomics identified tricarboxylic acid (TCA) cycle components as previously unrecognized DDX1 interaction partners. Live-cell metabolomics highlighted that this interaction could impair TCA activity, which in turn resulted in enhanced mTORC1 activity. Consequently, genetic and pharmacologic disruption of mTORC1 resulted in pronounced cell death in vitro and in vivo. Thus, structurally linked coamplification of a passenger gene and an oncogene can result in collateral vulnerabilities. Significance: We demonstrate that coamplification of passenger genes, which were largely neglected in cancer biology in the past, can create distinct cancer dependencies. Because passenger coamplifications are frequent in cancer, this principle has the potential to expand target discovery in oncology. This article is featured in Selected Articles from This Issue, p. 384

1 March 2024
Verified
Other
Open access
YBYi Bei
Yi Bei
LBLuca Bramé
Luca Bramé
MKMarieluise Kirchner
Marieluise Kirchner
RFRaphaela Fritsche
Raphaela Fritsche
SKSeverine Kunz
Severine Kunz
AHAnton G. Henssen
Anton G. Henssen
Gene sets enriched in in cell lines after ectopic DDX1 expression.

1 March 2024
Verified
Other
Open access
YBYi Bei
Yi Bei
LBLuca Bramé
Luca Bramé
MKMarieluise Kirchner
Marieluise Kirchner
RFRaphaela Fritsche
Raphaela Fritsche
SKSeverine Kunz
Severine Kunz
AHAnton G. Henssen
Anton G. Henssen
Passenger genes are frequently coamplified with oncogenes in cancers and can be associated with distinct dependencies. A, The mean number of passenger genes coamplified with oncogenes compared with the frequency of oncogene amplifications in cancers (dot size presents incidence passenger gene coamplification). B, Number of cancer cell lines in CCLE with an oncogene amplification compared with the number of cell lines with passenger coamplification (oncogenes for which sufficient dependency information is available in the DepMap are marked in red). C, Chromosome 2 schematic highlighting the area of MYCN amplification and passenger genes recurrently included on the amplicon (top). Upset plot (bottom) for the coamplification frequency of three passenger genes, NBAS, DDX1, and FAM49A, identified on the MYCN amplicon in a cohort of 556 neuroblastomas. D, Top 10 GO ontology terms enriched for collateral lethal targets associated with DDX1-MYCN coamplifications (TOR complex labeled in red). E, Difference in gene dependency scores between cancer cell lines with DDX1-MYCN coamplification vs. cell lines with MYCN amplifications compared with the log-transformed P values (Wilcoxon; candidate collateral lethal dependencies in DDX1-MYCN coamplified cancer cells, blue; mTORC1 complex, red).

1 March 2024
Verified
Other
Open access
YBYi Bei
Yi Bei
LBLuca Bramé
Luca Bramé
MKMarieluise Kirchner
Marieluise Kirchner
RFRaphaela Fritsche
Raphaela Fritsche
SKSeverine Kunz
Severine Kunz
AHAnton G. Henssen
Anton G. Henssen
List of gene dependencies associated with DDX1 co-amplification.

1 March 2024
Verified
Other
Open access
YBYi Bei
Yi Bei
LBLuca Bramé
Luca Bramé
MKMarieluise Kirchner
Marieluise Kirchner
RFRaphaela Fritsche
Raphaela Fritsche
SKSeverine Kunz
Severine Kunz
AHAnton G. Henssen
Anton G. Henssen
DDX1 hijacks the α-KGDH complex resulting in α-KG accumulation and OXPHOS reduction. A, Relative concentrations of α-KG, citrate, and isocitrate in cancer cell lines with DDX1-MYCN coamplifications (red) compared with cells only harboring MYCN amplifications (blue; Welch t test, P = 0.038764, 0.008224, and 0.025814 for α-KG, citrate, and isocitrate, respectively; N = 4 independent MYCN-amplified cancer cell lines versus N = 8 independent cancer cell lines with DDX1-MYCN coamplification). B, Relative α-KG concentrations measured by GC-MS in KELLY cells ectopically expressing DDX1 or the DDX1-Δ269-295aa for 48 hours. KELLY cells transduced with an empty vector and exposed to doxycycline were used as control (Wilcox test, P = 0.02778; data are shown as mean ± standard error). C, Western immunoblot of DDX1, P70-S6K, P70-S6K Thr389 phosphorylation, and α-tubulin in IMR5/75 cells treated with DM-αKG (2 mmol/L for 48 hours) and expressing shRNA targeting either DLST or GFP as control. D, Mitochondrial oxygen consumption rate (OCR) measured using live-cell metabolic analysis at basal respiration, maximal respiration, and ATP production in KELLY cells inducibly expressing DDX1 or DDX1-Δ269-295aa for 48 hours. KELLY cell transduced with a doxycycline-inducible empty vector served as negative control (Welch t test, P = 0.002, 0.010, and 0.002 for basal respiration, maximal respiration, and ATP production, respectively; data are shown as mean ± SE; N = 4 independent replicates). E, Exemplary photomicrographs taken on a transmission electron microscope of cells expressing DDX1 compared with cells expressing DDX1 Δ269-295aa. Cells transduced with an empty vector well as cells not treated with doxycycline served as negative controls. F, Quantification of mitochondrial length (longest axis in a cross-section) of cells shown in E (Wilcox test, P = 0.7954, 7.028e−10, and 0.1453, independently).